Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical c...
Q1 2026
May 7, 2026
FY 2025
Feb 26, 2026
Q4 2025
Q3 2025
Oct 30, 2025
Q2 2025
Aug 7, 2025